Skip to main content
TTrialFinder
TrialFinder is for informational purposes only and does not provide medical advice. Always talk to your doctor.
RECRUITINGINTERVENTIONAL

Novel Digital Patient-Reported Outcomes Tool for Diabetes Management

iMatter2: An Artificial Intelligence (AI)-Driven Approach to Supercharge a Novel Digital Patient-reported Outcomes Tool for Diabetes Management

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.

About This Trial

Investigators will conduct a hybrid type 1 effectiveness-implementation randomized controlled trial (RCT) to evaluate the effectiveness of iMatter2 versus usual care on reduction in HbA1c at 12-months (primary outcome) among patients with Type 2 diabetes (T2D).

Who May Be Eligible (Plain English)

Who May Qualify: PCP Group: - Fulltime primary care provider (MD/DO, NP) practicing at the participating family health centers or faculty group practices and - Provide care to at least five patients with a diagnosis of T2D Patient Group: - Have a diagnosis of T2D for ≥6 months; - Have uncontrolled T2D defined as HbA1c \>7% documented in the EHR on at least two visits in the past year; - Fluency in English or Spanish; - Be willing to send/receive text messages; and - Be \> 18 years of age. Who Should NOT Join This Trial: Patient Group: - Refuse or are unable to provide willing to sign a consent form; - Have acute renal failure, end stage renal disease (ESRD) or evidence of dialysis, renal transplantation, or other ESRD-related services documented in the EHR; - Have significant psychiatric comorbidity or reports of substance abuse (as documented in the EHR); - Are pregnant or planning to become pregnant within 12 months; - Currently participate in another T2D study; or - Plan to discontinue care at the clinic within the next 12 months. Always talk to your doctor about whether this trial is right for you.

Original Eligibility Criteria

View original clinical language
Inclusion Criteria: PCP Group: * Fulltime primary care provider (MD/DO, NP) practicing at the participating family health centers or faculty group practices and * Provide care to at least five patients with a diagnosis of T2D Patient Group: * Have a diagnosis of T2D for ≥6 months; * Have uncontrolled T2D defined as HbA1c \>7% documented in the EHR on at least two visits in the past year; * Fluency in English or Spanish; * Be willing to send/receive text messages; and * Be \> 18 years of age. Exclusion Criteria: Patient Group: * Refuse or are unable to provide informed consent; * Have acute renal failure, end stage renal disease (ESRD) or evidence of dialysis, renal transplantation, or other ESRD-related services documented in the EHR; * Have significant psychiatric comorbidity or reports of substance abuse (as documented in the EHR); * Are pregnant or planning to become pregnant within 12 months; * Currently participate in another T2D study; or * Plan to discontinue care at the clinic within the next 12 months.

Treatments Being Tested

OTHER

Mobile Health (mHealth) Patient-Reported Outcome (PRO) tool

Once the program begins, the AI chatbot sends daily text messages that include the PRO questions; a link to a library of educational resources tailored to their responses and personalized motivational messages with support. Participants will also be sent links to the interactive web-based dashboard that visualizes their daily PRO and HbA1c data. PCPs will be able to view reports of patients' PRO and home A1c data through the EHR interface, which can be reviewed during visits with the patient or asynchronously to track patient PROs between visits.

Locations (1)

NYU Langone Health
New York, New York, United States